Global iodinated contrast media in interventional X-ray market is projected to register a substantial CAGR of 5.3 % in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research & Academic Institutes), Country ( U.S., Canada, Mexico,, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Belgium, Turkey, Rest Of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, UAE, Saudi Arabia, Egypt, South Africa, Israel, Rest of Middle East and Africa) Market Trends and Forecast to 2027

Some of the major factors contributing to the growth of the market are:
- Increasing health care expenditure
- Increasing genetic population

Market Players:
The key market players for global iodinated contrast media in interventional X-ray market are listed below:
- Bayer AG
- Iso-Tex Diagnostics, Inc.
- Bracco Diagnostic Inc.
- Novalek Pharmaceuticals Pvt. Ltd.
- iMAX
- Taejoon Pharm
- Unijules Life Sciences Ltd
- General Electric
- Guerbet LLC
- J.B.Chemicals & Pharmaceuticals Ltd